The likelihood of approval (LoA) for AMO Pharma’s AMO-01 in Phelan-McDermid Syndrome (PMS) with co-morbid epilepsy jumped 13 points as of 29 March, according to GlobalData’s LoA data. The score change was based on the completion of an investigator-sponsored, 6-patient Phase II at Mount Sinai Hospital on 31 March 2020, noted by a 24 March 2021 update to ClinicalTrials.gov.

London, UK-based AMO Pharma’s open-label Phase II (NCT03493607), which has not yet published results, used the number of adverse events during the eight weeks following administration as its primary endpoint. Secondary endpoints include physician-measured efficacy assessments such as the Clinical Global Impression – Improvement Scale and the Visual Analogue Scale. Subjects received a single, 6-hour intravenous infusion of AMO-01 at the onset of the study, totalling 120 mg/m2 of treatment, according to Clinical Trials.gov. AMO Pharma provided AMO-01 and grant funding for the investigator-sponsored trial, according to a May 2018 company press release.

While the LoA prior to this news was 5%, GlobalData’s analysis using a combination of machine learning and a proprietary algorithm has raised the LoA to 18%. AMO-01 inhibits the Ras-extracellular signal-regulated kinase pathway inhibitor, which could improve behavioural abnormalities and seizures in patients with the neurodevelopment disorder PMS.

William Newton is a Healthcare Reporter for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.